Luis Roque, Jesus Molpeceres, Claudia Reis, Patrícia Rijo and Catarina Pinto Reis* Pages 280 - 290 ( 11 )
Candida species remain a significant cause of nosocomial bloodstream infections, associated with prolonged hospital stay in the ICU and high healthcare cost. The incidence of Candida is very high in certain risk groups of patients (AIDS, diabetes, cancer, etc.). Recent developments of nanotechnology have strongly contributed to the design of new multifunctional drug carriers that improve drug bioavailability through a controlled and prolonged release profile or even through a more specific targeted delivery of the antifungal agent. Those types of systems have strongly increased with a progressive generation of new structures, permitting the conjunction of new materials, biomolecules, physical and chemical techniques, for better outcomes. Nanotechnology shows expanded possibilities within the medical field and in the case of the yeast infections it may overcome several issues related with the fungal proliferation or higher inhibition of the pathogen causing the infection. This review covers a period of the most representative research of Candidiasis since 1993 to the present.
Fungal infections, candidiasis, encapsulation, antifungal agents, nanoparticles, mucoadhesion.
CBiOS - Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, 1749-024 Lisboa, Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcala, Ctra. A2 km 33,600, 28871 Alcala de Henares, Centro Hospitalar de Tras-os-montes e Alto Douro, iMed.ULisboa - Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, CBIOS, Universidade Lusofona de Humanidades e Tecnologias, P.O. Box: 1749-024, Lisboa